178 related articles for article (PubMed ID: 26452313)
1. A Uridine Glucuronosyltransferase 2B7 Polymorphism Predicts Epirubicin Clearance and Outcomes in Early-Stage Breast Cancer.
Sawyer MB; Pituskin E; Damaraju S; Bies RR; Vos LJ; Prado CM; Kuzma M; Scarfe AG; Clemons M; Tonkin K; Au HJ; Koski S; Joy AA; Smylie M; King K; Carandang D; Damaraju VL; Hanson J; Cass CE; Mackey JR
Clin Breast Cancer; 2016 Apr; 16(2):139-44.e1-3. PubMed ID: 26452313
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetic association between GSTP1 genetic polymorphism and febrile neutropenia in Japanese patients with early breast cancer.
Sugishita M; Imai T; Kikumori T; Mitsuma A; Shimokata T; Shibata T; Morita S; Inada-Inoue M; Sawaki M; Hasegawa Y; Ando Y
Breast Cancer; 2016 Mar; 23(2):195-201. PubMed ID: 25008867
[TBL] [Abstract][Full Text] [Related]
3. Uridine Glucuronosyltransferase 2B7 Polymorphism-Based Pharmacogenetic Dosing of Epirubicin in FEC Chemotherapy for Early-Stage Breast Cancer.
Joy AA; Vos LJ; Pituskin E; Cook SF; Bies RR; Vlahadamis A; King K; Basi SK; Meza-Junco J; Mackey JR; Stanislaus A; Damaraju VL; Damaraju S; Sawyer MB
Clin Breast Cancer; 2021 Oct; 21(5):e584-e593. PubMed ID: 33832852
[TBL] [Abstract][Full Text] [Related]
4. Correlation of UGT2B7 Polymorphism with Cardiotoxicity in Breast Cancer Patients Undergoing Epirubicin/Cyclophosphamide-Docetaxel Adjuvant Chemotherapy.
Li H; Hu B; Guo Z; Jiang X; Su X; Zhang X
Yonsei Med J; 2019 Jan; 60(1):30-37. PubMed ID: 30554488
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer.
Masuda N; Higaki K; Takano T; Matsunami N; Morimoto T; Ohtani S; Mizutani M; Miyamoto T; Kuroi K; Ohno S; Morita S; Toi M
Cancer Chemother Pharmacol; 2014 Aug; 74(2):229-38. PubMed ID: 24871032
[TBL] [Abstract][Full Text] [Related]
6. Impact of genetic variability and treatment-related factors on outcome in early breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide, and docetaxel.
Vulsteke C; Pfeil AM; Schwenkglenks M; Pettengell R; Szucs TD; Lambrechts D; Peeters M; van Dam P; Dieudonné AS; Hatse S; Neven P; Paridaens R; Wildiers H
Breast Cancer Res Treat; 2014 Oct; 147(3):557-70. PubMed ID: 25168315
[TBL] [Abstract][Full Text] [Related]
7. Impact of UGT2B7 His268Tyr polymorphism on the outcome of adjuvant epirubicin treatment in breast cancer.
Parmar S; Stingl JC; Huber-Wechselberger A; Kainz A; Renner W; Langsenlehner U; Krippl P; Brockmöller J; Haschke-Becher E
Breast Cancer Res; 2011 Jun; 13(3):R57. PubMed ID: 21658222
[TBL] [Abstract][Full Text] [Related]
8. Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II - III invasive breast cancer: the OOTR-N001 study.
Chow LW; Tung SY; Ng TY; Im SA; Lee MH; Yip AY; Toi M; Glück S
Expert Opin Investig Drugs; 2013 Mar; 22(3):299-307. PubMed ID: 23394482
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
[TBL] [Abstract][Full Text] [Related]
10. Effects of FGFR gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-docetaxel-based chemotherapy in breast cancer patients.
Chen L; Qi H; Zhang L; Li H; Shao J; Chen H; Zhong M; Shi X; Ye T; Li Q
BMC Cancer; 2018 Oct; 18(1):1038. PubMed ID: 30359238
[TBL] [Abstract][Full Text] [Related]
11. Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC).
Vulsteke C; Lambrechts D; Dieudonné A; Hatse S; Brouwers B; van Brussel T; Neven P; Belmans A; Schöffski P; Paridaens R; Wildiers H
Ann Oncol; 2013 Jun; 24(6):1513-25. PubMed ID: 23396606
[TBL] [Abstract][Full Text] [Related]
12. Feasibility and safety of weekly sequential epirubicin-paclitaxel as adjuvant treatment for operable breast cancer patients older than 70 years.
Ladoire S; Rambach L; Quipourt V; Favier L; Ghiringhelli F; Arnould L; Pfitzenmeyer P; Fumoleau P; Coudert B
Clin Breast Cancer; 2011 Aug; 11(4):235-40. PubMed ID: 21737355
[TBL] [Abstract][Full Text] [Related]
13. Relative Prognostic and Predictive Value of Gene Signature and Histologic Grade in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
Iwamoto T; Kelly C; Mizoo T; Nogami T; Motoki T; Shien T; Taira N; Hayashi N; Niikura N; Fujiwara T; Doihara H; Matsuoka J
Clin Breast Cancer; 2016 Apr; 16(2):95-100.e1. PubMed ID: 26631838
[TBL] [Abstract][Full Text] [Related]
14. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
[TBL] [Abstract][Full Text] [Related]
15. ER, PgR, Ki67, p27(Kip1), and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab.
Kurozumi S; Inoue K; Takei H; Matsumoto H; Kurosumi M; Horiguchi J; Takeyoshi I; Oyama T
BMC Cancer; 2015 Sep; 15():622. PubMed ID: 26345461
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
Joensuu H; Kellokumpu-Lehtinen PL; Huovinen R; Jukkola-Vuorinen A; Tanner M; Kokko R; Ahlgren J; Auvinen P; Paija O; Helle L; Villman K; Nyandoto P; Nilsson G; Pajunen M; Asola R; Poikonen P; Leinonen M; Kataja V; Bono P; Lindman H
J Clin Oncol; 2012 Jan; 30(1):11-8. PubMed ID: 22105826
[TBL] [Abstract][Full Text] [Related]
17. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
Arslan UY; Turker I; Aksoy S; Oksuzoglu B; Helvaci K; Yildirim Ozdemir N; Uyeturk U; Uysal Sonmez O; Budakoglu B; Zengin N
J BUON; 2013; 18(3):585-93. PubMed ID: 24065468
[TBL] [Abstract][Full Text] [Related]
18. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H
Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556
[TBL] [Abstract][Full Text] [Related]
19. Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.
Rastogi P; Buyse ME; Swain SM; Jacobs SA; Robidoux A; Liepman MK; Pajon ER; Dy PA; Posada JG; Melnik MK; Piette F; Geyer CE; Mamounas EP; Wolmark N
Clin Breast Cancer; 2011 Aug; 11(4):228-34. PubMed ID: 21684812
[TBL] [Abstract][Full Text] [Related]
20. Dose-intensified epirubicin versus standard-dose epirubicin/cyclophosphamide followed by CMF in breast cancer patients with 10 or more positive lymph nodes: results of a randomised trial (GABG-IV E-93) - the German Adjuvant Breast Cancer Group.
Eiermann W; Graf E; Ataseven B; Conrad B; Hilfrich J; Massinger-Biebl H; Vescia S; Loibl S; von Minckwitz G; Schumacher M; Kaufmann M;
Eur J Cancer; 2010 Jan; 46(1):84-94. PubMed ID: 19879750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
